Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer.

Dyson G, Farran B, Bolton S, Craig DB, Dombkowski A, Beebe-Dimmer JL, Powell IJ, Podgorski I, Heilbrun LK, Bock CH.

Am J Cancer Res. 2018 Oct 1;8(10):2088-2095. eCollection 2018.

2.

Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer.

Ginsburg KB, Auffenberg GB, Qi J, Powell IJ, Linsell SM, Montie JE, Miller DC, Cher ML.

Eur Urol. 2018 Dec;74(6):704-707. doi: 10.1016/j.eururo.2018.08.010. Epub 2018 Aug 31.

PMID:
30177290
3.

A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer.

Farran B, Dyson G, Craig D, Dombkowski A, Beebe-Dimmer JL, Powell IJ, Podgorski I, Heilbrun L, Bolton S, Bock CH.

Carcinogenesis. 2018 Apr 5;39(4):556-561. doi: 10.1093/carcin/bgy025.

5.

Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.

Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, Hofree M, Romanel A, Osborne JR, Kim JW, Azabdaftari G, Woloszynska-Read A, Sfanos K, De Marzo AM, Demichelis F, Gabriel S, Van Allen EM, Mesirov J, Tamayo P, Rubin MA, Powell IJ, Garraway LA.

Cancer Discov. 2017 Sep;7(9):973-983. doi: 10.1158/2159-8290.CD-16-0960. Epub 2017 May 17.

6.

Legends in Urology.

Powell IJ.

Can J Urol. 2017 Feb;24(1):8605-8608. No abstract available.

7.

REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants.

Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, Holzinger E, Karyadi D, Cannon-Albright LA, Teerlink CC, Stanford JL, Isaacs WB, Xu J, Cooney KA, Lange EM, Schleutker J, Carpten JD, Powell IJ, Cussenot O, Cancel-Tassin G, Giles GG, MacInnis RJ, Maier C, Hsieh CL, Wiklund F, Catalona WJ, Foulkes WD, Mandal D, Eeles RA, Kote-Jarai Z, Bustamante CD, Schaid DJ, Hastie T, Ostrander EA, Bailey-Wilson JE, Radivojac P, Thibodeau SN, Whittemore AS, Sieh W.

Am J Hum Genet. 2016 Oct 6;99(4):877-885. doi: 10.1016/j.ajhg.2016.08.016. Epub 2016 Sep 22.

8.

Considering race and the potential for ERG expression as a biomarker for prostate cancer.

Powell IJ, Dyson G, Chinni SR, Bollig-Fischer A.

Per Med. 2014;11(4):409-412.

9.

Editorial comment.

Powell IJ.

Urology. 2014 Dec;84(6):1441. doi: 10.1016/j.urology.2014.08.043. No abstract available.

PMID:
25432836
10.

Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men.

Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1505-11. doi: 10.1158/1055-9965.EPI-13-1328. Epub 2014 May 6.

11.

Minireview: the molecular and genomic basis for prostate cancer health disparities.

Powell IJ, Bollig-Fischer A.

Mol Endocrinol. 2013 Jun;27(6):879-91. doi: 10.1210/me.2013-1039. Epub 2013 Apr 22. Review.

12.

Genes associated with prostate cancer are differentially expressed in African American and European American men.

Powell IJ, Dyson G, Land S, Ruterbusch J, Bock CH, Lenk S, Herawi M, Everson R, Giroux CN, Schwartz AG, Bollig-Fischer A.

Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):891-7. doi: 10.1158/1055-9965.EPI-12-1238. Epub 2013 Mar 20.

13.

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM Jr.

J Urol. 2012 Oct;188(4):1164-9. doi: 10.1016/j.juro.2012.06.046. Epub 2012 Aug 22.

14.

Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.

Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP 3rd, Crawford ED, Thompson IM Jr, Klein EA.

Urology. 2012 Mar;79(3):633-7. doi: 10.1016/j.urology.2011.11.019.

15.

The precise role of ethnicity and family history on aggressive prostate cancer: a review analysis.

Powell IJ.

Arch Esp Urol. 2011 Oct;64(8):711-9. Review. English, Spanish.

16.
17.
18.

Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer.

Schwartz K, Powell IJ, Underwood W 3rd, George J, Yee C, Banerjee M.

Urology. 2009 Dec;74(6):1296-302. doi: 10.1016/j.urology.2009.02.058.

19.

Results from a prostate cancer admixture mapping study in African-American men.

Bock CH, Schwartz AG, Ruterbusch JJ, Levin AM, Neslund-Dudas C, Land SJ, Wenzlaff AS, Reich D, McKeigue P, Chen W, Heath EI, Powell IJ, Kittles RA, Rybicki BA.

Hum Genet. 2009 Nov;126(5):637-42. doi: 10.1007/s00439-009-0712-z. Epub 2009 Jul 1.

20.

Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities.

Williams H, Powell IJ.

Methods Mol Biol. 2009;472:439-53. doi: 10.1007/978-1-60327-492-0_21. Review.

PMID:
19107447
21.

A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men.

Ellison GL, Weinrich SP, Lou M, Xu H, Powell IJ, Baquet CR.

J Natl Med Assoc. 2008 Oct;100(10):1139-45.

22.

A decision aid for teaching limitations of prostate cancer screening.

Weinrich SP, Seger RE, Rao GS, Chan EC, Hamm RM, Godley PA, Moul JW, Powell IJ, Chodak GW, Taylor KL, Weinrich MC.

J Natl Black Nurses Assoc. 2008 Jul;19(1):1-11.

PMID:
18807773
23.

Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases.

Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T, Pettaway CA, Vijayakumar S, Weinrich S, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD, Kittles RA.

Prostate. 2008 Dec 1;68(16):1790-7. doi: 10.1002/pros.20841.

24.

The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer.

Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ.

Urology. 2008 Jan;71(1):151-5. doi: 10.1016/j.urology.2007.08.016.

PMID:
18242385
25.

Knowledge of hereditary prostate cancer among high-risk African American men.

Weinrich S, Vijayakumar S, Powell IJ, Priest J, Hamner CA, McCloud L, Pettaway C.

Oncol Nurs Forum. 2007 Jul;34(4):854-60.

PMID:
17723986
26.

Validation of a food frequency questionnaire measurement of selected nutrients using biological markers in African-American men.

Holmes MD, Powell IJ, Campos H, Stampfer MJ, Giovannucci EL, Willett WC.

Eur J Clin Nutr. 2007 Nov;61(11):1328-36. Epub 2007 Feb 7.

PMID:
17299490
27.

Epidemiology and pathophysiology of prostate cancer in African-American men.

Powell IJ.

J Urol. 2007 Feb;177(2):444-9. Review.

PMID:
17222606
28.

African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.

Yanke BV, Carver BS, Bianco FJ Jr, Simoneaux WJ, Venable DD, Powell IJ, Eastham JA.

BJU Int. 2006 Oct;98(4):783-7.

29.

Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.

Bangsi D, Zhou J, Sun Y, Patel NP, Darga LL, Heilbrun LK, Powell IJ, Severson RK, Everson RB.

Urol Oncol. 2006 Jan-Feb;24(1):21-7.

PMID:
16414488
30.

Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma.

Altinok G, Powell IJ, Che M, Hormont K, Sarkar FH, Sakr WA, Grignon D, Liao DJ.

Prostate Cancer Prostatic Dis. 2006;9(1):77-82.

PMID:
16331298
31.

A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history.

Kittles RA, Baffoe-Bonnie AB, Moses TY, Robbins CM, Ahaghotu C, Huusko P, Pettaway C, Vijayakumar S, Bennett J, Hoke G, Mason T, Weinrich S, Trent JM, Collins FS, Mousses S, Bailey-Wilson J, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD.

J Med Genet. 2006 Jun;43(6):507-11. Epub 2005 Sep 9.

32.

Breast carcinoma metastatic to the bladder and renal pelvis requiring fulguration.

Fisher MB, Weise AJ, Powell IJ.

Clin Breast Cancer. 2005 Jun;6(2):173-4.

PMID:
16001997
33.

The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy.

Powell IJ, Land SJ, Dey J, Heilbrun LK, Hughes MR, Sakr W, Everson RB.

Cancer. 2005 Feb 1;103(3):528-37.

34.

CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy.

Powell IJ, Zhou J, Sun Y, Sakr WA, Patel NP, Heilbrun LK, Everson RB.

J Urol. 2004 Nov;172(5 Pt 1):1848-52.

PMID:
15540736
35.

Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy.

Williams H, Powell IJ, Land SJ, Sakr WA, Hughes MR, Patel NP, Heilbrun LK, Everson RB.

Prostate. 2004 Nov 1;61(3):267-75.

PMID:
15368470
36.

Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer.

Bianco FJ Jr, Wood DP Jr, Cher ML, Powell IJ, Souza JW, Pontes JE.

Clin Prostate Cancer. 2003 Mar;1(4):242-7.

PMID:
15040883
37.

The effect of race/ethnicity on prostate cancer treatment outcome is conditional: a review of Wayne State University data.

Powell IJ, Banerjee M, Bianco FJ, Wood DP Jr, Dey J, Lai Z, Heath M, Pontes EJ.

J Urol. 2004 Apr;171(4):1508-12.

PMID:
15017209
38.

Radical prostatectomy nomograms in black American men: accuracy and applicability.

Bianco FJ Jr, Kattan MW, Scardino PT, Powell IJ, Pontes JE, Wood DP Jr.

J Urol. 2003 Jul;170(1):73-6; discussion 76-7.

PMID:
12796648
39.

African-American heredity prostate cancer study: a model for genetic research.

Powell IJ, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu CA, Boykin W, Mason T, Royal C, Baffoe-Bonnie A, Bailey-Wilson J, Berg K, Trent J, Collins F.

J Natl Med Assoc. 2001 Apr;93(4):120-3.

40.

Presence of circulating prostate cancer cells in African American males adversely affects survival.

Bianco FJ Jr, Powell IJ, Cher ML, Wood DP Jr.

Urol Oncol. 2002 Jul-Aug;7(4):147-52.

PMID:
12474530
41.

Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109.

Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, Osswald MB, DeVERE WHITE R, Thompson IM Jr, Crawford ED.

J Urol. 2002 Nov;168(5):2016-9.

PMID:
12394698
42.

Prostate specific antigen progression after radical prostatectomy in African-American men versus white men.

Banerjee M, Powell IJ, George J, Biswas D, Bianco F, Severson RK.

Cancer. 2002 May 15;94(10):2577-83.

43.

Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy.

Bianco FJ Jr, Wood DP Jr, Grignon DJ, Sakr WA, Pontes JE, Powell IJ.

J Urol. 2002 Aug;168(2):479-82.

PMID:
12131292
44.

Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis.

Powell IJ, Dey J, Dudley A, Pontes JE, Cher ML, Sakr W, Grignon DJ, Wood DP.

Urology. 2002 Jun;59(6):907-12.

PMID:
12031379
45.

African-American heredity prostate cancer study: a model for genetic research.

Powell IJ, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu CA, Boykin W, Mason T, Royal C, Baffoe-Bonnie A, Bailey-Wilson J, Berg K, Trent J, Collins F.

J Natl Med Assoc. 2001 Dec;93(12 Suppl):25S-28S.

46.
47.

Biochemical recurrence after radical prostatectomy in black and white American men with a positive or negative family history of prostate cancer.

Narain V, Tiguert R, Banerjee M, Grignon D, Wood DP, Powell IJ.

J Urol. 2001 Feb;165(2):474-7.

PMID:
11176399
48.

8pter-p23 deletion is associated with racial differences in prostate cancer outcome.

Washburn JG, Wojno KJ, Dey J, Powell IJ, Macoska JA.

Clin Cancer Res. 2000 Dec;6(12):4647-52.

49.

Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival.

Sakr WA, Tefilli MV, Grignon DJ, Banerjee M, Dey J, Gheiler EL, Tiguert R, Powell IJ, Wood DP.

Urology. 2000 Nov 1;56(5):730-4.

PMID:
11068289
50.

Impact of location and multifocality of positive surgical margins on disease-free survival following radical prostatectomy: a comparison between African-American and white men.

Shekarriz B, Tiguert R, Upadhyay J, Gheiler E, Powell IJ, Pontes JE, Grignon DJ, Sakr W, Wood DP.

Urology. 2000 Jun;55(6):899-903.

PMID:
10840105

Supplemental Content

Loading ...
Support Center